Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage
Source: SeekingAlpha
2026-02-12 10:45:34 ET
More on Organon
- Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
- Organon: Deep Value With No Clear Catalysts
- Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
- Organon falls as women’s health unit drives Q4 miss
- Organon Non-GAAP EPS of $0.63 misses by $0.10, revenue of $1.51B in-line
Read the full article on Seeking Alpha
For further details see:
Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage
Organon & Co.
NASDAQ: OGN
OGN Trading
-1.9% G/L:
$6.46 Last:
859,864 Volume:
$6.50 Open:
OGN Latest News
February 27, 2026 08:00:00 am
New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
February 23, 2026 07:30:00 am
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
OGN Stock Data
$2,031,766,457
254,887,247
0.05%
304
N/A
Pharmaceuticals
Healthcare
US
Jersey City
